Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Baltimore, Maryland, 21205, United States
Location status: Recruiting
Recruiting
NCT Number: NCT07209176
Physician- and Patient-based Barriers to NGS Testing
The goal of this study is to improve next-generation sequencing (NGS) testing rates at Johns Hopkins in patients with metastatic prostate cancer. Investigators believe by targeting two barriers, provider-level and patient-level, will improve the testing rate of NGS at Johns Hopkins.
Recruiting
Interested in participating?
Request InfoKey information
Conditions
Age range
18 year and older
Sex eligibility
Male
Study type
Interventional
Phase
Not applicable
Primary location
About this study
Next-generation sequencing is recommended by national guidelines in metastatic prostate cancer to inform prognosis, treatment decisions, and eligibility for clinical trials. However, rates are low nationally and around 50-60% at Johns Hopkins. Analysis found that older patients and patients who are not married are less likely to have testing performed. The goals and objectives of this proposed clinical trial are to improve NGS testing rates at Johns Hopkins using a multidisciplinary approach to improve the care of patients living with metastatic prostate cancer and reduce disparities. The hypothesis is that this initiative, which targets two barriers (provider-level and patient-level), will lead to higher rates of NGS ordering at Johns Hopkins.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- men diagnosed with metastatic prostate cancer
- seen by Johns Hopkins Medical Oncology as a new patient visit between January 1, 2025 and December 31, 2026
Exclusion criteria
- Patients who have already had NGS testing performed.
Treatment and study plan
Provider-level and patient education at end of study
OtherThe provider level component will involve an email to each of the genitourinary medical oncologists at Johns Hopkins with their NGS testing rate from preliminary data and compare this rate to the mean. The initial email will also include the 2025 ASCO guideline recommending somatic testing in virtually all metastatic prostate cancer patients. Providers who do not have baseline NGS testing rates available will also be emailed. Providers will subsequently be emailed their updated NGS testing rate at the conclusion of the study period.
Patients will also receive a one-page patient educational material (via email, or mail if no email on file) on advanced prostate cancer that includes education on somatic NGS testing at the end of the study period.
Provider-level and patient-level
OtherIn addition to the provider component, patients will also receive a one-page patient educational material (via email, or mail if no email on file) on advanced prostate cancer that includes education on somatic NGS testing. The email will be sent by the MyChart Recruitment Innovation team. Those without email on file will have the same message and attachment sent via mail by our study coordinator.
Primary outcomes
-
Rate of Next-Generation Sequencing (NGS) testing by arm
Time frame: 1 year
Secondary outcomes
-
Percentage of patients with sociodemographic and clinical characteristics who have had NGS testing compared to those without NGS testing during the study period.
Time frame: 1 year
Study contacts
Contact information is provided by the study sponsor or research team.
Catherine Marshall, MD
CONTACT
Maddie Klugman
CONTACT
Sponsors and collaborators
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Collaborators
- Pfizer
Registry information
Official study title
A Clinical Trial to Address Physician- and Patient-based Barriers to NGS Testing
Important dates
- Study start
- 2026
- Primary completion
- 2027
- Study completion
- 2027
- First posted
- Oct 6, 2025
- Registry last updated
- Feb 3, 2026
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Recruiting
Collection of Blood From Patients With Prostate Cancer
NCT00923221
Cancer Of Prostate, Genital Diseases
Bethesda, Maryland, United States
View Trial Details
Recruiting
Duration of Androgen Receptor Pathway Inhibitor and ADT With Metastasis Directed Therapy in Oligometastatic Cancer of the Prostate (DIRECT)
NCT05404139
Genital Diseases, Genital Diseases, Male
Toronto, Ontario, Canada
View Trial Details
Recruiting
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
NCT05011383
Genital Diseases, Genital Diseases, Male
Aurora, Colorado, United States
View Trial Details
Recruiting
Evaluating Dose Timing (Morning vs Evening) of Endocrine-based Therapies in Metastatic Breast and Prostate Cancers
NCT07252726
Breast Diseases, Breast Neoplasms
Kitchener, Ontario, Canada
View Trial Details